Oppenheimer Reiterates Outperform Rating on Brickell Biotech (BBI)

Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $4.00 price target on Brickell Biotech Inc. (NASDAQ: BBI), following the company's Q4 report.

The analyst quotes: "BBI reported 4Q net loss of $6.1M vs our $8.9M estimate on lower R&D expense. An NDA filing for SB gel in primary axillary hyperhidrosis is on track to be submitted mid-year, and possibilities to monetize this asset in exchange for non-dilutive capital are being actively explored. Early-stage candidates BBI-02 (DYRK1A inhibitor, for autoimmune and inflammatory conditions) and BBI-10 (covalent STING inhibitor, for auto-inflammatory and rare genetic disorders) are progressing through preclinical activities, with the former to enter the clinic next quarter."

For an analyst ratings summary and ratings history on Brickell Biotech Inc. click here. For more ratings news on Brickell Biotech Inc. click here.

Shares of Brickell Biotech Inc. closed at $0.22 yesterday.

By Vlad Schepkov | [email protected]

You May Also Be Interested In